



#7 #1

**CERTIFICATE OF MAILING (37 C.F.R. §1.8 (a))**

I hereby certify that the attached papers or fee are being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

8/13/02

(Date)

Angela L. Kratky

(Printed Name)

Angela Kratky

(Signature)

**DOCKET NO.: 70332-4/US**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: **Ghildyal *et al.***

Application No.: **10/040,884**

Group Art Unit: **1646**

Filed: **January 7, 2002**

Examiner: **Not yet assigned**

For: **Human Receptor Tyrosine Kinase**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Applicants submit herewith a list of patents and publications which Applicants believe may be material to the patentability of claims of the above-identified application and for which there may be a duty to disclose in accordance with 37 C.F.R. §1.56.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. §1.56.


Some of the references (marked with an asterisk) listed on the attached Form PTO-1449 were submitted to the Patent and Trademark Office during the prosecution of prior filed U.S. Application Number 09/310,438, which application is relied upon for an earlier filing date under 35

**DOCKET NO.: 70332-4/US  
PATENT APPLICATION**

**SERIAL NO.: 10/040,884  
FILED: JANUARY 7, 2002**


This Information Disclosure Statement is being filed before the mailing date of a first office action on the merits and therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is required pursuant to 37 C.F.R. § 1.17(p).

Respectfully submitted,



**Robin S. Quartin, Ph.D.**  
Registration No. 45,028  
(302) 885-9129

Date: *August 13, 2002*



Form PTO-1249 <b>INFORMATION DISCLOSURE CITATION BY APPLICANT</b> <i>(Use s v r a l s h e t s i f n e c e s s a r y)</i>	DOCKET NUMBER 70332-4/US	APPLICATION NUMBER 10/040,884
	APPLICANT Ghildyal <i>et al.</i>	
	FILING DATE January 7, 2002	GROUP ART UNIT 1646

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	* 5,763,584	06-09-1998	Godowski	530	402	
	* 5,763,470	06-09-1998	Tang <i>et al.</i>	514	406	
	* 5,763,198	06-09-1998	Hirth <i>et al.</i>	435	7.21	
	* 5,763,441	06-09-1998	App <i>et al.</i>	514	249	

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 97/34920	09-25-1997	PCT				
	WO 95/30331	11-16-1995	PCT				

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	* Shawver <i>et al.</i> , 1997, Receptor tyrosine kinases as targets for inhibition of angiogenesis, Drug Discovery Today, 2:50-63.
	* Herz <i>et al.</i> , 1997, Molecular approaches to receptors as targets for drug discovery, J. Recept. Signal Transduct. Res., 17:671-776 .
	Marra <i>et al.</i> , The WashU-HHMI mouse EST project, EMBL ACC NO AA098024, 27 October 1996.
	Auffray <i>et al.</i> , IMAGE: integrated molecular analysis of the human genome and its expression, EMBL ACC NO Z42722, 6 November 1994.
	Rubin Grandis <i>et al.</i> , Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells, Oncogene, 15:409-416.

\* COPIES PREVIOUSLY SUBMITTED WITH THE PATENT APPLICATION, SERIAL NO. 09/310,438.

Form PTO-1449  <b>INFORMATION DISCLOSURE CITATION BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>	DOCKET NUMBER 70332-4/US	APPLICATION NUMBER 10/040,884
	APPLICANT Ghildyal <i>et al.</i>	
	FILING DATE January 7, 2002	GROUP ART UNIT 1646

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	Chou <i>et al.</i> , 1987, Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin, J. Bio. Chem., 262:1842-1847.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.